Recent findings suggest endomyocardial biopsy may be avoidable in cases of patients with similar plasma cell dyscrasia test results. Read More ›

This study suggests a lack of association of increased survival benefit with use of neurohormonal blockade therapies; however, future research is warranted. Read More ›

Despite similar rates of major bleed and stroke among African American and Caucasian patients with transthyretin cardiac amyloidosis, African American patients present with fewer cases of atrial fibrillation. Read More ›

In a retrospective analysis at a single center, 15% of patients with light chain amyloidosis cardiomyopathy had significant myocardial uptake on a 99mTc-PYP scan. Read More ›

Tafamidis-treated ATTR-CM patients observed stable functional status and biomarkers, despite a higher proportion of worse NYHA functional class in this real-world population. Read More ›

Both atrial and ventricular arrhythmias are common manifestations of cardiac amyloidosis, frequently necessitating implantation of cardiac electronic devices. Read More ›

Female ATTR V122I patients present predominantly with polyneuropathy phenotype at a younger age, while males present with predominantly cardiovascular or mixed phenotype. Read More ›

Internal quality control and continued education for technologists and readers of PYP scans are important to avoid misdiagnosis. A standardized protocol for evaluation of cardiac amyloidosis could help eliminate variability in testing patterns. Read More ›

Based on data from 3 international sites, transcatheter aortic valve replacement should not be withheld in patients with both aortic stenosis and cardiac amyloidosis. Read More ›

Acoramidis (AG10) displays differential TTR binding, kinetic stability, and a higher degree of stabilization compared with tafamidis. Read More ›

Page 1 of 2

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.